Study finds frailty risks with GLP-1 drugs in older adults

A new study finds that while rare, frailty signals in older adults taking GLP-1 drugs like Zepbound are linked to high risks of adverse outcomes, including a 25-fold increased risk of death with malnutrition. The nference study, which comes as Medicare expands GLP-1 access to millions of seniors, urges closer monitoring but does not discourage appropriate use. Researchers advise physicians to intervene aggressively at the first sign of frailty.

Frailty risks in older adults

• ▪A study found that potential signs of frailty in older adults taking Eli Lilly's GLP-1 drug Zepbound may signal high risks for adverse outcomes.
• ▪Frailty-associated conditions like malnutrition, dehydration, and muscle loss developed rarely in older adults using GLP-1 drugs, according to a new study.
• ▪In patients taking Zepbound (tirzepatide), frailty conditions typically emerged after six months of treatment.
• ▪GLP-1 drugs Zepbound and Wegovy have been shown to provide benefits including significant weight reduction and better blood sugar control.
• ▪The study found progressive muscle decline in 0.16% of patients, malnutrition in 1.6%, dehydration in 3%, and loss of appetite in 4.75%.

Study methodology with three cohorts

• ▪The study's findings do not show that the drug tirzepatide caused the adverse outcomes observed.
• ▪The nference study compared nearly 30,000 adults 65+ on Zepbound, 19,000 on non-GLP-1 diabetes drugs, and 6,000 post-weight-loss surgery.
• ▪A study on GLP-1 drugs by U.S. data analytics firm nference was released as a preprint on July 13, 2026 and has been submitted for peer review.
• ▪The study focused on Zepbound (tirzepatide) because previous analyses linked it with more weight and muscle loss than Wegovy (semaglutide).

Mortality risks with malnutrition

• ▪For comparison, malnutrition increased the death risk seven-fold for users of other diabetes drugs and two-fold for bariatric surgery patients.
• ▪The risk of death was six-fold higher among tirzepatide users who developed dehydration compared to those who did not.
• ▪Tirzepatide users who developed malnutrition had a 25-fold higher risk of related death over 18 months compared to users without the condition.
• ▪Muscle wasting was associated with a 12-fold increased risk of death in tirzepatide users.

Medicare GLP-1 coverage expansion

• ▪Over 41% of U.S. adults aged 60 and older are obese, according to the Centers for Disease Control and Prevention.
• ▪An estimated 3 to 4 million older adults in the U.S. may qualify for GLP-1 obesity drugs under the new Medicare program.
• ▪As of July 1, 2026, eligible Medicare Part D beneficiaries can access GLP-1 obesity drugs for a $50 monthly copay.

Clinical monitoring recommendations

• ▪The study's senior author advised physicians to intervene aggressively if frailty signals appear, including stopping tirzepatide treatment.
• ▪The study's researchers recommended closer monitoring for older patients on GLP-1 drugs but said results should not discourage appropriate use.
• ▪UCLA endocrinologist Dr. Preethi Srikanthan stated clinicians should be aware of frailty risks but not be alarmed or avoid the effective treatment.

1 source